22:01 , Jun 17, 2019 |  BC Extra  |  Financial News

Viela's $75M series B to support BLA, autoimmune pipeline

After attracting multiple crossover investors to its latest venture round, Viela’s $75 million series B could be the last private round for the MedImmune spinout. HBM Healthcare Investments led the financing with participation from fellow...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
01:37 , Feb 15, 2019 |  BC Week In Review  |  Financial News

CStone could get $1.5B valuation in Hong Kong IPO

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) would be valued at HK$11.8 billion ($1.5 billion) if it prices its Hong Kong IPO at the midpoint of its proposed range. The cancer company plans to sell 186.4...
19:49 , Feb 14, 2019 |  BC Extra  |  Financial News

CStone could get $1.5B valuation in Hong Kong IPO

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) would be valued at HK$11.8 billion ($1.5 billion) if it prices its Hong Kong IPO at the midpoint of its proposed range. The cancer company plans to sell 186.4...
17:03 , Jan 4, 2019 |  BC Week In Review  |  Financial News

China's Antengene raises $120M series B round

Antengene Corp. (Shanghai, China) completed a $120 million series B round on Jan. 2 to fund development of its two lead cancer compounds, selinexor and ATG-008. Boyu Capital and FountainVest led the round, with participation...
21:56 , Jan 2, 2019 |  BC Extra  |  Financial News

China's Antengene raises $120M series B round

Antengene Corp. (Shanghai, China) completed a $120 million series B round to fund development of its two lead cancer compounds, selinexor and ATG-008. Boyu Capital and FountainVest led the round, with participation by Celgene Corp....
15:57 , Nov 16, 2018 |  BC Week In Review  |  Financial News

CStone lines up for Hong Kong IPO

With an anti-PD-L1 mAb in Phase III testing and cornerstone investors such as WuXi Ventures and Boyu Capital, immuno-oncology company CStone Pharmaceuticals Co. Ltd. (Suzhou, China) proposed to list on the Hong Kong stock exchange...
23:43 , Nov 12, 2018 |  BC Extra  |  Financial News

CStone lines up for Hong Kong IPO

With an anti-PD-L1 mAb in Phase III testing and cornerstone investors such as WuXi Ventures and Boyu Capital, immuno-oncology company CStone Pharmaceuticals Co. Ltd. (Suzhou, China) on Monday proposed to list on the Hong Kong...
18:47 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Harbin Gloria selling stake in biotech unit to new investors

Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) said Aug. 17 it plans to sell a 51% stake in biotech subsidiary Guangzhou Gloria Biotechnology Co. Ltd. (Guangzhou, China) to 6 Dimensions Capital, Boyu Capital and two other...
23:37 , Aug 17, 2018 |  BC Extra  |  Financial News

Harbin Gloria selling stake in biotech unit

Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) said Friday it plans to sell a 51% stake in biotech subsidiary Guangzhou Gloria Biotechnology Co. Ltd. (Guangzhou, China) to 6 Dimensions Capital, Boyu Capital and two other investors....